BioSpace News Archive

MindBio Therapeutics Corp. Chief Executive Officer Justin Hanka provides video update on Phase 2a Depression trial using MB22001.

Evofem Biosciences, Inc. today announced preliminary results for the third quarter of 2023, including sequential growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate) and the positive impact of ongoing cost containment initiatives.

ITM Isotope Technologies Munich SE reported on its participation at the 3rdInternational Centers for Precision Oncology Forum for Theranostics in Precision Oncology which took place in Garching near Munich, Germany, from October 12-13, 2023.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announced treatment of the first patient in the cholangiocarcinoma cohort of the BOLSTER Trial by Dr. Ian Hu, a principal investigator of the study, at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Collegium Pharmaceutical, Inc. announced that it will report third quarter 2023 financial results after the market closes on Tuesday, November 7, 2023.

NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for SNK01 natural killer (NK) cell therapy for treatment of moderate Alzheimer’s Disease (AD).

Foghorn® Therapeutics Inc. (Nasdaq: FHTX) today announced that the Company will present new data from multiple preclinical and clinical programs at the 6th Annual Targeted Protein Degradation (TPD) Summit and the Connective Tissue Oncology Society (CTOS) Annual Meeting.

Onconova Therapeutics, Inc. announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer, and the addition of Meena Arora as Vice President, Global Medical Affairs and Research and Development.

Avenge Bio, Inc. today announced their poster presentation at the Society of Immunotherapy of Cancer 38th Annual Meeting (SITC 2023) on November 1-5, 2023, in San Diego, California.